Bidard, F. C., Seban, R., Ven, S. M. V. D., Ladoire, S., Alberini, J., Bellesoeur, A., Martino, S. P., Humbert, O., Mounat, T. C., Deshayes, E., Djaileb, L., Kerrou, K., Deluche, E., Cochet, A. (2026). [
                    <sup>18</sup>
                    F] Fluoroestradiol PET/CT to guide second-line treatment decision-making in patients with estrogen receptor–positive, HER2-negative advanced breast cancer after progression on first-line aromatase inhibitor and CDK4/6 inhibitor: Primary results of ESTROTIMP.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1077